Theraclion S.A.
ALTHE.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.03 | -0.02 | 0.07 |
| FCF Yield | -26.44% | -9.50% | -9.32% | 0.00% |
| EV / EBITDA | -6.16 | -4.31 | -5.20 | -7.29 |
| Quality | ||||
| ROIC | -29.43% | -30.43% | -22.32% | 0.12% |
| Gross Margin | -353.48% | -1,039.28% | -708.37% | -49.28% |
| Cash Conversion Ratio | 1.40 | 0.52 | 0.64 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.11% | -9.07% | -7.84% | -13.53% |
| Free Cash Flow Growth | -158.84% | 6.23% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.99 | 0.99 | 0.82 | 3.60 |
| Interest Coverage | -37.59 | -296.67 | -265.07 | 2.07 |
| Efficiency | ||||
| Inventory Turnover | 1.78 | 2.09 | 1.13 | 0.43 |
| Cash Conversion Cycle | 258.28 | 117.20 | 678.76 | 611.44 |